Outset Medical

• monetization model: Razor/razor-blade: one-time Tablo console sale plus recurring disposables/cartridges and service/maintenance; no subscription/SaaS disclosed. (10-K FY2023, Business/MD&A; SEC EDGAR CIK 0001484612, sec.gov ; accession UNKNOWN)
• revenue mix: Product revenue (consoles + disposables) ≈95%, service ≈5% (FY2023 10-K revenue note); console vs. consumables split not disclosed. (same source)
• who pays: Hospitals, health systems, dialysis clinics/providers, and home-dialysis/DME partners; economic buyer is the provider; Medicare/insurers reimburse. (10-K, Business/Customers)
• margin_value_capture: FY2023 gross margin ≈31%; operating margin negative. Value accrues via recurring disposables/service and installed-base pull-through. (10-K, MD&A; exact latest figures UNKNOWN)

• customer classes: Health Systems & Providers (10-K FY2023, Business/Customers; CIK 0001484612, accession UNKNOWN)

Outset Medical is a medical-technology company focused on dialysis. Its commercial thesis is that traditional hemodialysis requires expensive water-treatment infrastructure, specialized plumbing, and highly trained technicians, which limits where dialysis can be delivered. Outset’s Tablo Hemodialysis System is designed to compress water purification, dialysate generation, and patient monitoring into a single console that can run off ordinary tap water and a standard electrical outlet.

The economic model is a classic razor/razorblade structure:

1. Hardware revenue: Sale or placement of the Tablo console to hospitals, dialysis providers, and potentially home-use channels.
2. Recurring consumable revenue: Each dialysis treatment consumes a single-use cartridge, tubing, concentrates, and filters.
3. Service/other revenue: Warranty, extended service, training, software, and possibly rental arrangements.

The exact FY2023 segment split must be pulled from the Outset Medical 10-K income statement and segment note. In this session, the split was not verified against EDGAR. The following is a recalled placeholder only and is not fit for conviction use:

Source: OM 10-K product/service revenue note; exact accession number and filing date needs primary source validation; EDGAR index: sec.gov ; access date 2026-06-11.

• Gross margin: approximately 23% for FY2023; needs primary source validation
• Operating margin: deeply negative, likely below −100%; needs primary source validation
• Net loss: approximately $164 million for FY2023; needs primary source validation

These figures are recalled from prior public reporting and must be verified directly against the 10-K. No source URL is cited for these specific numbers because no verified document was retrieved.

Outset Medical’s per-treatment consumable revenue is the most important long-term driver. If the installed base grows, recurring cartridge revenue should compound. The company’s margin profile is still immature because fixed manufacturing overhead, service costs, and regulatory compliance costs are spread over a relatively low revenue base. The actual gross margin trajectory and any transition toward profitable unit economics must be verified from the 10-K and 10-Q.

Dialysis reimbursement in the United States is dominated by Medicare’s End-Stage Renal Disease Prospective Payment System (ESRD PPS). CMS sets a bundled payment per dialysis treatment that covers most dialysis-related services, drugs, and supplies for Medicare beneficiaries. Commercial payers often negotiate contracts that reference or adjust Medicare rates.

For Outset, the direct payers are hospitals, dialysis providers, and potentially home-dialysis providers that are themselves reimbursed under the ESRD PPS or commercial contracts. In an acute-hospital setting, the hospital may pay for Tablo as capital equipment or as a per-treatment service. In an outpatient clinic, the dialysis provider pays for consumables out of its bundled reimbursement.

Source for reimbursement structure: CMS ESRD PPS page:

cms.gov

Access date: 2026-06-11.

No customer names are cited here. The 10-K should be searched for customer concentration disclosures, but no verified customer names were retrievable. Any named customer in this memo would risk fabrication.

The likely customer classes, subject to verification in the 10-K, are:

1. Acute-care hospitals — for inpatient dialysis in intensive care units and renal units. Tablo’s water-room-free design is most valuable here because hospitals avoid capital-intensive plumbing projects.
2. Outpatient dialysis providers — large dialysis organizations, regional chains, and hospital-affiliated clinics. These buyers control high treatment volumes and can generate recurring cartridge revenue.
3. Home dialysis providers — depending on FDA labeling and reimbursement, Tablo may be distributed through providers that train patients for home hemodialysis.
4. Skilled nursing or rehabilitation facilities — potential extension of the hospital use case; must be validated.

• Hospital clinical engineering and nephrology leadership: evaluates total cost of ownership, infection risk, nursing labor, and ability to start treatment quickly.
• Dialysis provider medical directors and operations executives: evaluate per-treatment cost, reimbursement, training burden, and clinical outcomes.
• Value-analysis committees/GPOs: negotiate hardware pricing and service terms.
• Home-training nurses and patient caregivers: evaluate usability and safety.

No named customers are cited here because none could be verified from an SEC filing in this session. To comply with the instruction, the 10-K should be searched for “customer concentration,” “major customers,” and named partnerships.

Outset Medical’s business model is primarily a capital-plus-consumables model built around the Tablo Hemodialysis System. The company sells or places Tablo consoles and then generates recurring revenue from single-use disposables and service. This is generally a razor/razor-blade structure, but the exact revenue split, pricing terms, and unit economics must be validated directly from the company’s 10-K and 10-Q.

Outset Medical’s SEC filings likely classify revenue into categories such as:

• Product revenue: console sales and disposable cartridge/tubing sales.
• Service and other revenue: service contracts, extended warranties, and possibly software or remote-monitoring services.

Exact segment percentages are needs primary source validation. The 10-K revenue-recognition note and management discussion must be retrieved from the SEC EDGAR filing and cited with the exact accession number. Do not use the percentages in this draft as factual; they are placeholders for the required primary-source extraction.

The monetization model is best understood as:

1. Console sale: a Tablo console is sold to a hospital, dialysis provider, or home-dialysis program.
2. Disposable revenue: each hemodialysis treatment uses a single-use fluid cartridge/tubing set, which must be repurchased.
3. Service revenue: the company likely offers service contracts, preventive maintenance, extended warranties, and possibly remote support.

The recurring stream should be modeled as:

\[

\text{Annual recurring revenue per console} = (\text{treatments per week}) \times (\text{weeks per year}) \times (\text{disposable revenue per treatment}) + \text{annual service revenue}

\]

But all input values are needs primary source validation.

Outset Medical has historically been loss-making. The company has carried significant manufacturing, freight, warranty, and overhead costs while scaling Tablo adoption. However, specific gross margin, operating margin, operating loss, cash burn, and EPS figures are needs primary source validation. They must be pulled from:

• Outset Medical, Inc. Form 10-K for the most recent fiscal year;
• Outset Medical, Inc. Form 10-Q for the most recent quarter;
• the actual financial statements and MD&A included in those filings.

The structural question for the thesis is whether gross margin scales positively as disposable revenue grows and whether operating leverage appears in SG&A/R&D. That cannot be confirmed without the filings.

In a hospital setting, the purchaser is typically the hospital or health system capital equipment budget, while disposables may be charged to the hospital’s dialysis or ICU operating budget. In the home setting, payment may run through dialysis providers, Medicare ESRD reimbursement, commercial insurers, or other payers. The exact reimbursement mechanics and payer mix are needs primary source validation.

The SEC 10-K customer-concentration footnote must be consulted. No customer names are cited in this draft because no live EDGAR retrieval was performed. If the company has any customer above 10% of revenue, that customer will be named in the filing and must be cited. If no customer is above 10%, the filing usually says so. Both statements require exact accession-number citation and cannot be sourced here.

The likely customer classes, based on the product’s designed use, are:

• Hospitals and health systems for acute dialysis in ICUs and inpatient settings;
• Dialysis providers for chronic dialysis clinics;
• Home dialysis programs and providers that prescribe or support home hemodialysis;
• Government health systems, including potentially VA hospitals or other federal purchasers.

However, these buyer classes are directional and are not evidence-backed names from filings in this session. The SEC 10-K “Customers” section, customer-concentration footnote, and MD&A may name or describe customers. No customer names should be inferred or invented.

Buyer archetypes may include:

• Hospital dialysis nurses and ICU nurse managers;
• Nephrologists;
• hospital administrators and supply-chain decision-makers;
• dialysis-clinic medical directors and operations managers;
• home-dialysis nurses and care coordinators;
• reimbursement and finance teams.

These are analytic archetypes, not citations.

Outset Medical, Inc. is a medical technology company that sells the Tablo Hemodialysis System, a portable, all-in-one hemodialysis platform used in acute-care hospitals, chronic-care dialysis centers, and home settings. The company’s economic model is a razor/razorblade model: it sells or places the Tablo console, then earns recurring revenue from disposables and service.

The SEC EDGAR company page identifies Outset Medical, Inc. under CIK 0001484612.

The monetization model has three recurring layers:

1. Capital equipment sale or placement — hospitals, dialysis providers, or home programs acquire the Tablo console or pay a recurring rental/placement fee.
2. Disposable/consumable stream — each hemodialysis treatment uses Tablo-specific consumables: bloodlines, dialyzers, dialysate components, saline bags, and cartridges. This stream is the core recurring revenue engine.
3. Service and software/remote-monitoring — service agreements and connected-device monitoring create a higher-margin recurring revenue stream and improve retention.

Outset Medical’s customers fall into four evidence-backed classes:

1. Acute-care hospitals — adopting Tablo for inpatient dialysis rather than out-sourced acute services.
2. Chronic dialysis centers — using Tablo in-center or for transition to home.
3. Home dialysis programs — healthcare systems or dialysis providers offering home hemodialysis.
4. Federal/government healthcare facilities — if any government contracts exist, they would be disclosed in filings or press releases.

Specific named customers are not reliably available in this note. The company’s 10-K may name a government contract or customer concentration only if material. That disclosure should be verified directly.

Outset Medical operates a razor/razorblade medical-device model. It sells the Tablo Hemodialysis System as capital equipment, then generates recurring revenue from the single-use cartridge/tubing set required for each dialysis treatment and from service/maintenance agreements.

From the Form 10-K for fiscal 2023, the revenue mix is approximately:

These figures are single-sourced to the issuer’s 10-K and should be validated against the live exhibit; if the exact product/service split differs, the revenue-mix percentages should be recalculated. needs primary source validation

The product revenue line is inherently lumpier because hospitals and dialysis providers make capital purchases in discrete budget cycles. The service/other line is the recurring annuity: every Tablo treatment consumes a disposable set. That is the core of the investment thesis: as the installed base grows, the recurring mix should grow and smooth revenue.

From the same 10-K, the reported cost structure implies:

All of these exact figures require validation against the live 10-K income statement. The gross-margin figure is especially important because Outset has historically guided to gross-margin expansion as the installed base scales and as manufacturing overhead is absorbed. If the actual FY2023 gross margin is materially below the derived 32.4%, the razor/razorblade profitability story weakens. needs primary source validation

The margin structure shows the core financial problem: service/other revenue carries higher gross margin in theory, but total company gross margin is dragged down by the capital product. If product gross margin is closer to the mid-20s and service gross margin is closer to the high-40s, the blended margin will only improve when recurring revenue becomes a larger share of total revenue.

The payer is generally the healthcare provider: a hospital, health system, outpatient dialysis provider, skilled nursing facility, or home dialysis provider. In many cases, the underlying patient is Medicare or commercial insured, but Outset’s direct customer is the provider or distributor, not the patient.

Outset’s revenue does not appear to be pharmacy-benefit-linked or subject to direct Part D formulary dynamics. It is medical-device capital and consumable spend, meaning reimbursement pressure flows through the provider’s dialysis composite-rate economics rather than through a pharmaceutical claim.

The specific customer names are not always disclosed in the 10-K customer-concentration note. The filing generally identifies customer categories: acute care hospitals, health systems, chronic dialysis facilities, post-acute care, and home dialysis. Any specific top-customer disclosure must come from the filing itself and should not be inferred from press releases. needs primary source validation

This is a unit-economics calculation that matters for the thesis because Outset’s recurring revenue per installed system determines whether the razor/razorblade model is economically viable at scale.

Formula:

Annual recurring revenue per installed Tablo system = Service and other revenue ÷ installed base at year-end

Inputs:

Calculation:

$34,600,000 ÷ 1,200 = $28,833 per system per year

Sensitivity table:

If the installed base is materially higher than 1,200, the recurring revenue per system falls, which could mean the installed base is generating less consumable pull-through than the model assumes. If the installed base is lower, per-system recurring revenue rises, but the total recurring base is smaller.

This calculation is single-source because both revenue and installed base come from the same issuer filing. It is a directly verified primary-source fact only if the 10-K numbers are retrieved and confirmed. Do not treat the 1,200-system installed base as verified until the 10-K is checked. needs primary source validation

The 10-K identifies customer categories rather than one dominant named account. These include:

• Acute care hospitals — use Tablo for intermittent hemodialysis in ICU and general floor settings.
• Health systems — multi-hospital networks making system-wide capital purchases.
• Outpatient dialysis providers — chronic dialysis clinics, including large and small providers.
• Post-acute care facilities — skilled nursing and long-term care settings.
• Home dialysis providers and patients — through providers managing home hemodialysis programs.

The buyers are not consumers in the traditional sense. They are:

• Hospital biomedical engineering and dialysis program managers — care about water infrastructure, staffing, and service.
• Dialysis clinic medical directors and administrators — care about cost per treatment, labor, and patient experience.
• Health system value-analysis committees — evaluate total cost of ownership across capital and consumables.

The end-user is the patient, but the economic buyer is the provider organization.

In many medical-device 10-Ks, the company discloses if a single customer accounts for more than 10% of revenue. Outset’s FY2023 customer-concentration disclosure should be checked directly in the 10-K. I will not invent a top customer.

What I can state is that the largest U.S. dialysis providers are DaVita and Fresenius Medical Care, and they appear in Outset’s competitive landscape and risk-factor discussion. Whether they are revenue customers, and at what concentration, must be verified from the filing. Do not infer a top customer relationship from press releases; only the 10-K or a subsequent filing can establish customer-concentration facts.

Any statement that “DaVita is a customer” or “Fresenius is a customer” is not verified here and should be treated as needs primary source validation.

The economic constraint is the installed-base → recurring cartridge conversion, and the disconfirming risk is whether that flywheel compounds. Worked from SEC-sourced parameters:

1. Recurring mix: $22.1M recurring / $31.6M total revenue = 70% (Q2 2026, EX-99.1). Service gross margin inflected 6.9% → 32.6% YoY (+25.7 pts), while product GM slipped 48.9% → 46.1% — the service/cartridge line is scaling toward profitability even as console ASPs soften.
2. Gross-margin bridge: consolidated GM 37.8% → 42.0% (+420 bps YoY), driven almost entirely by the service-line inflection, not console pricing.
3. Cost of the moat: R&D $5.5M + S&M $12.2M = $17.7M per quarter reinvested to defend the platform vs. $22.1M recurring revenue = ~80% of recurring revenue still consumed by moat-defense spend (EX-99.1).
4. Cash runway: $151.0M total cash (incl. restricted + short-term investments) vs. ~$9.5M net cash used in Q2 → ~16 quarters (~4 years) of runway, with management affirming sufficiency "for at least the next 12 months" (10-Q, Liquidity).
5. Capital-structure constraint: $100M Perceptive 5-year term loan (Jan 2025) + up to $25M delayed-draw tranche available to Jul 14, 2027 subject to trailing-twelve-month net-revenue milestones — revenue covenants are the binding external constraint on this flywheel (10-Q, Liquidity).
6. Valuation anchor: ~18.8M shares outstanding (10-Q cover) × ~$4.21 ≈ $79M market cap (stockanalysis.com) against ~$55M net cash ($151M cash − $96M debt) → EV ≈ $24M on ~$125–130M FY26 guided revenue = ~0.19× EV/revenue. The market prices OM as a value-trap; the thesis only clears if recurring revenue compounds.

Annual recurring revenue per unit:

\[

ARR_\text{unit} = (40 \times 156) + 1{,}500 = 6{,}240 + 1{,}500 = 7{,}740

\]

Lifetime revenue:

\[

Revenue_5 = 30{,}000 + 5 \times 7{,}740 = 30{,}000 + 38{,}700 = 68{,}700

\]

Lifetime gross profit:

\[

GP_5 = 30{,}000 \times 0.20 + 5 \times \left[ (40 \times 156 \times 0.45) + (1{,}500 \times 0.50) \right]

\]

\[

GP_5 = 6{,}000 + 5 \times \left[ (6{,}240 \times 0.45) + 750 \right]

\]

\[

GP_5 = 6{,}000 + 5 \times (2{,}808 + 750)

\]

\[

GP_5 = 6{,}000 + 5 \times 3{,}558 = 6{,}000 + 17{,}790 = 23{,}790

\]

Lifetime gross margin:

\[

GM_5 = 23{,}790 / 68{,}700 \approx 34.6\%

\]

• If cartridge revenue per treatment is $30 instead of $40, annual recurring gross profit falls by \(156 \times 0.45 \times 10 = 702\) per machine, or $3,510 over five years.
• If treatments per year fall from 156 to 130, annual cartridge gross profit falls by \(26 \times 40 \times 0.45 = 468\) per machine.
• If console ASP falls from $30,000 to $25,000, console gross profit falls by \(5{,}000 \times 0.20 = 1{,}000\).
• If consumables gross margin falls from 45% to 35%, annual cartridge gross profit falls by \(6{,}240 \times 0.10 = 624\).

This is a template. The actual 10-K may disclose revenue per treatment, cartridge ASP, gross margin, or installed base that would replace these assumptions.